Medical Director, Dermatologist & Mohs Surgeon
Location: Calgary North
Languages: English
Clinical Focus: Mohs Micrographic Surgery, Laser Surgery, Neuromodulators, Dermal Fillers
Dr. Danny Guo is a double board-certified dermatologist specializing in medical, surgical, and cosmetic dermatology. He serves as Medical Director at the Calgary North location, with a primary focus on the surgical management of skin cancers and advanced procedural dermatology.
Dr. Guo completed his undergraduate training at the University of British Columbia, earning a Bachelor of Science in Cell Biology and Genetics. He went on to obtain a Master’s degree in Experimental Medicine from the University of Alberta, where he received multiple distinctions for research excellence, leadership, and community contribution, including the Stars of Alberta Award. He earned his Doctor of Medicine at the University of Calgary before returning to UBC to complete his dermatology residency, where he was appointed Chief Resident. His training includes advanced surgical and cosmetic experience across more than 15 leading institutions in North America and Asia. Following board certification in both Canada and the United States, Dr. Guo completed fellowship training in Mohs Micrographic Surgery at the University of Toronto.
Dr. Guo’s clinical and research interests include skin cancer surgery, laser-based treatments, injectable therapies, and the integration of teledermatology to improve access to care.
Rejuvenation Dermatology’s Clinical Trials Department is a national, multi-site research network dedicated to advancing dermatologic care through ethically conducted, regulated clinical research. Integrated within routine clinical practice, the department partners with global pharmaceutical sponsors to evaluate novel therapies and offers early access to innovative treatment options. The team supports industry-sponsored and investigator-initiated trials across a broad range of indications, collaborating closely with sponsors, CROs, investigators, and ethics boards to deliver high-quality data while maintaining a strong commitment to patient safety.
Since its inception, the division has evolved from a single research-focused clinic into a coordinated, multi-province research network. Today, it operates with standardized infrastructure, centralized oversight, and experienced investigators across Canada.
